Almac Group: Delivering Expertise Across the Drug Development Lifecycle and Offering Tailored Solutions to Clients Globally, in the Greater Philadelphia Region

Delivering Expertise Across the Drug Development Lifecycle and Offering Tailored Solutions to Clients Globally, in the Greater Philadelphia Region 

The Greater Philadelphia region has a long, storied history of being a global epicenter of healthcare. From groundbreaking cancer research conducted at leading institutions like the University of Pennsylvania, to the development of innovative biopharmaceuticals and gene therapies, the region boasts a diverse and talented group of global leaders dedicated to advancing health care and the life sciences.  

At Almac Group, we are proud to call Montgomery County home for our North American operations. We chose the Philadelphia region, specifically central Montgomery County, because this area supports our unique culture of delivering exceptional solutions and integrated services. 

The Almac Group is an established contract development and manufacturing organization providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Our innovative services range from R&D, biomarker discovery development and commercialization, API manufacturing, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) to commercial-scale manufacturing. 

We are a privately-owned, UK-based global company that has grown organically over the past five decades, currently employing over 6,500 highly skilled personnel across 18 facilities in Europe, the U.S. and Asia.  Founded by the late Sir Allen McClay, we are able to reinvest 100 percent of our profits back into the business – a strategy we are committed to. Our corporate structure provides long-term stability for our customers and for our employees while also allowing us to freely pursue investments designed to keep us at the forefront of our industry.  This is the recipe for Almac’s unique corporate culture, which marries the opportunity for employees to work in a genuinely caring and innovative workplace, while contributing to the valuable work of advancing human health. 

At Almac, we are trusted by leading biopharmaceutical companies around the world to provide a broad range of client services to support each critical phase of their drug development process. For example, last year, Almac was directly involved in the development of over 300 life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology and gene therapy. 

In the last five years alone, Almac has contributed to more than half of all globally approved New Molecular Entities and is currently supporting 30 percent of EU approved and pre-registered gene therapy products. Our position gives us a front-row seat on how drug development and clinical trials are continuing to evolve across the world. Our sponsors are increasingly expanding their pipelines, with particular focuses on new biologics, vaccines and other advanced therapy products. And of course, as we witnessed during the COVID-19 pandemic, the rapid deployment of vaccines and therapeutic drugs to combat the virus required unprecedented speed and efficiency in the drug development process. 

We are at the forefront of ensuring supply chain expertise and the capacity to support this evolution; and for us, that means we must continue to grow.  

Looking forward, our next three to five years in the Greater Philadelphia region are exciting. In the summer of 2022, we announced our plans to invest over $90 million on a range of expansion projects at our facilities in Montgomery County as well as create more than 350 new jobs in the Greater Philadelphia community. More recently, we were thrilled to reveal the largest of these projects – a $65 million, 100,000 square foot expansion of our clinical supply operations in Souderton. This capital plan will increase our clinical capacity at the site by 60 percent, providing additional cold, ultra-low and cryogenic storage and just-in-time processing capabilities.   

We will break ground in 2023, and upon completion, the added capacity will immediately support research organizations with their continued development of new biologics, gene and cell therapies and further advanced medicinal products.    

As we continue to grow in our work, we recognize and appreciate the support we have received and the strong relationships we have fostered as members of the British American Business Council. Our partnership with the BABC serves as a prime example of how successful collaborations are able to directly benefit communities and the life sciences industry, such as those in the Greater Philadelphia region. 

For more information and to keep up-to-date with latest news, follow us on Twitter and LinkedIn or visit  

Leave a Reply

↑ back to top

The BABCPHL recognizes our Club Level Members:

  • Almac
  • American Airlines
  • Baker Tilly
  • Cigna
  • Cigna
  • Duane Morris
  • EisnerAmper LLP
  • Faegre Drinker Biddle & Reath LLP
  • Forensic Resolutions
  • Johnson, Kendall & Johnson, Inc.
  • Johnson Matthey
  • Morgan Lewis
  • Olympus
  • Penn Medicine
  • Welsh Government